Center for Pre-Clinical Cancer Research

临床前癌症研究中心

• 批准号: 10795511
• 负责人: JOSEPH FRANCIS
• 金额: $ 25万
• 依托单位: LOUISIANA STATE UNIV A&M COL BATON ROUGE
• 依托单位国家: 美国
• 财政年份: 2023
• 资助国家: 美国
• 起止时间: 2023-03-01 至 2026-02-28
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10795511
• 关键词: 3-Dimensional; Address; Animal Diseases; Animal Model; Cell Culture System; Centers of Research Excellence; Complement; Core Facility; Culture Techniques; Disease; Disease model; Equipment; Evaluation; Exhibits; Extramural Activities; Funding; Human; In Vitro; Individual; Infrastructure; Malignant Neoplasms; Malignant neoplasm of liver; Malignant neoplasm of prostate; Mentorship; Modeling; Molecular Biology; Outcome; Patients; Pre-Clinical Model; Research; Research Personnel; Resources; Therapeutic; Training; anticancer research; clinically relevant; human disease; immunopathology; in vivo; insight; malignant breast neoplasm; mouse model; novel therapeutic intervention; novel therapeutics; osteosarcoma; pre-clinical; preclinical evaluation; therapy outcome; three dimensional cell culture; translational therapeutics; tumor; tumor microenvironment; tumorigenesis

Project Summary The Center for Pre-Clinical Cancer Research (Cancer COBRE) aims to identify clinically relevant mechanisms of human cancer disease using models that closely reflect the disease state in the context of the tumor microenvironment. Recent advances in 3D tumor culture techniques have intensified the focus on in vitro human cell culture systems to reveal insights into human tumorigenesis and thus drive novel therapeutic discovery. Promising Junior Investigators (PJIs) address devastating human cancer diseases that exhibit poor outcomes in patients and for which there are unmet therapeutic needs. The PJI projects feature osteosarcoma, breast cancer, liver cancer, and prostate cancer as diseases that would benefit from pre-clinical models that are more predictive of mechanistic efficacy in humans. All of the PJI projects will use specialized in vivo mouse models and/or in vitro 3D tumor spheroids to identify relevant mechanisms of tumorigenesis or for evaluation of novel therapeutic strategies. The Center will promote a unified and coordinated approach by establishing a new specialized core facility, Pre- Clinical Evaluation Core (PCEC), to provide scientific expertise and technical support for the pre-clinical evaluation of the PJI projects. The unique PCEC will provide a centralized approach that will support exploratory and translational assessment of cancer disease mechanisms and therapeutic strategies in humans. To accomplish this approach, advanced 3D cell culture systems will provide critical translational information. and bridge the gap between animal models and human therapeutic outcomes. The new Molecular Biology and Immunopatholgy Core (MBIPC) will provide access to state-of-the-art equipment and expertise in Molecular Biology and Immunopathology while leveraging extensive resources at LSU SVM. Human and animal diseases are a major focus at the LSU SVM and on the LSU campus. The Center has three Aims: Aim 1. To create a Center for Pre-Clinical Cancer Research to promote and support centralized management and coordination of pre-clinical evaluation of tumorigenesis mechanisms and translational therapeutic approaches. Aim 2. To provide the COBRE PJIs and other investigators with a core infrastructure for resources and support for advanced pre-clinical cancer disease research that will enhance PJI individual competitiveness for extramural funding. Aim 3. To provide training and mentorship on pre-clinical evaluation using state-of-the-art in vitro 3D tumor spheroids to complement in vivo cance disease modeling. Page 134

项目总结

项目成果

Challenges in the combination of radiotherapy and immunotherapy for breast cancer.

乳腺癌放射治疗和免疫治疗相结合的挑战。

• DOI: 10.1080/14737140.2023.2188196
• 发表时间: 2023
• 期刊: Expert review of anticancer therapy
• 影响因子: 3.3
• 作者: Zhang,Rui;Clark,SamanthaD;Guo,Beibei;Zhang,Tianyi;Jeansonne,Duane;Jeyaseelan,SamithambyJ;Francis,Joseph;Huang,Weishan
• 通讯作者: Huang,Weishan

Prevalence of antibiotic use for dogs and cats in United States veterinary teaching hospitals, August 2020.

• DOI: 10.1111/jvim.16814
• 发表时间: 2023-09
• 期刊: Journal of veterinary internal medicine
• 影响因子: 2.6
• 作者: Beaudoin AL;Bollig ER;Burgess BA;Cohn LA;Cole SD;Dear JD;Fellman CL;Frey E;Goggs R;Johnston A;Kreuder AJ;KuKanich KS;LeCuyer TE;Menard J;Reagan KL;Sykes JE;Veir JK;Viviano K;Wayne A;Granick JL
• 通讯作者: Granick JL

Inactivation of the UL37 Deamidase Enhances Virus Replication and Spread of the HSV-1(VC2) Oncolytic Vaccine Strain and Secretion of GM-CSF.

• DOI: 10.3390/v15020367
• 发表时间: 2023-01-27
• 期刊: Viruses
• 作者: Clark CM;Jambunathan N;Collantes TMA;Kousoulas KG
• 通讯作者: Kousoulas KG

Pathology in Practice.

病理学实践。

• DOI: 10.2460/javma.21.01.0017
• 发表时间: 2022
• 期刊: Journal of the American Veterinary Medical Association
• 作者: Hu,TriciaG;Dehghanpir,ShannonD;Sasaki,Emi;Costa,VictoriaR;Pucheu-Haston,CherieM;Piero,FabioDel;Withers,SitaS
• 通讯作者: Withers,SitaS

The use of 'trend' statements in veterinary oncology literature.

• DOI: 10.1111/vco.12811
• 发表时间: 2022-09
• 期刊: VETERINARY AND COMPARATIVE ONCOLOGY
• 影响因子: 2.1
• 作者: Groves, Priscilla K.;Liu, Chin-Chi;Geels, Olivia R.;Withers, Sita S.
• 通讯作者: Withers, Sita S.